EcoDrugPlus

Activin A Receptor Type 2b

Ensembl ID : ENSSTUG00000033724
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin Receptor Type-2b

Ensembl ID : ENSSTUG00000023035
Gene Symbol: LOC115150309
3 Cross references
187 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSSTUG00000026188
Gene Symbol: LOC115195559
3 Cross references
187 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSSTUG00000015536
Gene Symbol: ADORA1
3 Cross references
198 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSSTUG00000027464
Gene Symbol: ADORA1
3 Cross references
187 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSSTUG00000017295
Gene Symbol: ADORA2A
3 Cross references
190 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSSTUG00000039103
Gene Symbol: ADORA2A
3 Cross references
193 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSSTUG00000021339
Gene Symbol: ADORA2AA
1 Cross references
184 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSSTUG00000016383
Gene Symbol: ADORA3
3 Cross references
133 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSSTUG00000021200
Gene Symbol: ADORA3
3 Cross references
134 Possible Orthologues:

Adenosine Deaminase-Like

Ensembl ID : ENSSTUG00000026718
Gene Symbol: LOC115165576
3 Cross references
210 Possible Orthologues:

Adenosine Deaminase-Like

Ensembl ID : ENSSTUG00000004856
Gene Symbol: LOC115167917
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).